The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CELZ | -8.64% | N/A | N/A | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +236% |
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Its products include CaverStem, FemCelz, StemSpine, and ImmCelz. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.
No news articles found for Creative Medical Technology.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | -6.1% |
| Gross Margin | -959.23% | 0.0% |
| Market Cap | $8.59M | 107.2% |
| Market Cap / Employee | $2.15M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$1.24M | -18.8% |
| EBITDA | -$1.24M | -15.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.38M | -14.1% |
| Inventory | 0 | -70.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -93.58% | -38.8% |
| Return On Invested Capital | 15.52% | -38.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.17M | -18.6% |
| Operating Free Cash Flow | -$1.17M | -18.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.47 | 0.60 | 0.85 | 1.26 | 131.02% |
| Price to Sales | 346.79 | 307.01 | 1139.73 | 1432.20 | 265.02% |
| Price to Tangible Book Value | 0.51 | 0.65 | 0.90 | 1.35 | 135.58% |
| Enterprise Value to EBITDA | 1.14 | 2.09 | -0.24 | -2.59 | -243.96% |
| Return on Equity | -65.8% | -70.4% | -79.9% | -98.1% | 72.08% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
